U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C4H9NO2S
Molecular Weight 135.185
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MECYSTEINE

SMILES

COC(=O)[C@@H](N)CS

InChI

InChIKey=MCYHPZGUONZRGO-VKHMYHEASA-N
InChI=1S/C4H9NO2S/c1-7-4(6)3(5)2-8/h3,8H,2,5H2,1H3/t3-/m0/s1

HIDE SMILES / InChI
Mecysteine is used as a mucolytic in respiratory disorders associated with productive cough. Mecysteine is known as a mucolytic agent, it breaks down mucus. It works by breaking some of the chemical bonds between the molecules in mucus. It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days. Mecysteine has also been given by inhalation.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VISCLAIR

Approved Use

Visclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm.
Primary
VISCLAIR

Approved Use

Visclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm.
Primary
VISCLAIR

Approved Use

Visclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm.
PubMed

PubMed

TitleDatePubMed
Cysteine methyl ester modified glassy carbon spheres for removal of toxic heavy metals from aqueous media.
2005 Aug 7
Maillard reaction products derived from thiol compounds as inhibitors of enzymatic browning of fruits and vegetables: the structure-activity relationship.
2005 Jun
Kinetics and mechanistic studies of the hydrolysis of diisocyanate-derived bis-thiocarbamates of cysteine methyl ester.
2006 Mar
Mathematical modelling and simulation of adsorption processes at spherical microparticles.
2006 Mar 13
Kinetics of Cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration.
2006 Nov
Observation of cysteine thiolate and -S...H-O intermolecular hydrogen bond.
2006 Nov 23
Electrospray ionization and triple quadrupole tandem mass spectrometry study of some biologically relevant homo- and heterodimeric cadmium thiolate conjugates.
2006 Oct
One-electron reduction of S-nitrosothiols in aqueous medium.
2006 Oct 15
Antidiabetic zinc(II)-N-acetyl-L-cysteine complex: evaluations of in vitro insulinomimetic and in vivo blood glucose-lowering activities.
2007
Antiinflammatory and antifibrogenic effects of s-ethyl cysteine and s-methyl cysteine in the kidney of diabetic mice.
2007 May
Protective and alleviative effects from 4 cysteine-containing compounds on ethanol-induced acute liver injury through suppression of oxidation and inflammation.
2007 Sep
Aurintricarboxylic acid inhibits influenza virus neuraminidase.
2009 Feb
Synthesis, structural characterisation and anti-proliferative activity of NHC gold amino acid and peptide conjugates.
2009 Sep 21
Redetermination of di-μ-sulfido-bis-{[(2R)-2-acet-oxy-2-amino-ethane-1-thiol-ato-κN,S]oxidomolybdenum(V)}.
2010 Apr 24
hi2-1, a QTL which improves harvest index, earliness and alters metabolite accumulation of processing tomatoes.
2010 Nov
Gold nanoparticles conjugated to benzoylmercaptoacetyltriglycine and L-cysteine methylester.
2010 Oct 1
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Mecysteine has also been given by inhalation.
It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days.
Route of Administration: Oral
In Vitro Use Guide
The effects of L-cysteine methyl ester (Mecysteine) on behavior of mucus glycoproteins in canine tracheal secretory cells were investigated histologically and histochemically. Low concentrations (10(-7) and 10(-6)M) of L-cysteine methyl ester produced, as histological changes, decreases in the total goblet cell number and the thickness of the acini of submucosal glands, and an increase in the acinar inner diameter. On the other hand, L-cysteine methyl ester at 10(-5) and 10(-4)M produced an increase in the thickness of the acini and a slight decrease in the acinar inner diameter.
Name Type Language
MECYSTEINE
INN   MI   WHO-DD  
INN  
Official Name English
mecysteine [INN]
Common Name English
CYSTEINE METHYL ESTER
Systematic Name English
METHYL ESTER OF CYSTEINE
Common Name English
Mecysteine [WHO-DD]
Common Name English
METHYL CYSTEINE
Systematic Name English
MECYSTEINE [MI]
Common Name English
METHYL L-CYSTEINATE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C74536
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
Code System Code Type Description
CHEBI
41531
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL1622757
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
CAS
2485-62-3
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
EVMPD
SUB08688MIG
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
INN
1375
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
PUBCHEM
29145
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
RXCUI
29426
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
219-625-7
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
DRUG CENTRAL
1653
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
NCI_THESAURUS
C66067
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID8048365
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
MESH
C017507
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
SMS_ID
100000081968
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
FDA UNII
RQ6L463N3B
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
WIKIPEDIA
Mecysteine
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY
MERCK INDEX
m7126
Created by admin on Fri Dec 15 16:23:30 GMT 2023 , Edited by admin on Fri Dec 15 16:23:30 GMT 2023
PRIMARY Merck Index